Royalty Pharma plc
RPRX
$53.25
$1.553.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.80% | 5.06% | 3.70% | 3.02% | 1.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.80% | 5.06% | 3.70% | 3.02% | 1.13% |
| Cost of Revenue | -1,785.85% | -140.39% | -131.49% | -139.60% | -97.88% |
| Gross Profit | 25.18% | 74.65% | 41.19% | 117.56% | 84.82% |
| SG&A Expenses | 148.93% | 185.68% | 142.74% | 115.19% | 30.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 119.10% | -14.30% | 10.94% | -64.80% | -72.02% |
| Operating Income | -13.48% | 19.61% | 0.31% | 93.25% | 102.30% |
| Income Before Tax | -23.20% | -0.42% | -23.94% | 61.76% | 49.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.20% | -0.42% | -23.94% | 61.76% | 49.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 21.34% | -17.26% | 5.50% | -80.64% | -74.28% |
| Net Income | -24.35% | -10.13% | -33.11% | 51.76% | 36.89% |
| EBIT | -13.48% | 19.61% | 0.31% | 93.25% | 102.30% |
| EBITDA | -- | -- | 6.61% | -70.61% | -- |
| EPS Basic | -23.29% | -7.32% | -35.89% | 45.37% | 31.31% |
| Normalized Basic EPS | -18.07% | 16.04% | 3.15% | 194.08% | 338.28% |
| EPS Diluted | -23.27% | -7.51% | -36.02% | 45.25% | 31.26% |
| Normalized Diluted EPS | -18.10% | 9.89% | 10.70% | 211.29% | 366.95% |
| Average Basic Shares Outstanding | -3.90% | -4.62% | 4.83% | 5.66% | 7.23% |
| Average Diluted Shares Outstanding | -5.18% | -5.05% | -4.01% | -2.96% | -1.88% |
| Dividend Per Share | 5.29% | 4.76% | 4.82% | 4.88% | 4.94% |
| Payout Ratio | 0.35% | 0.12% | 0.52% | -0.33% | -0.24% |